DrugDashboards

Clindamycin phosphate

Clindamycin phosphate · CLINDAMYCIN PHOSPHATE 900 mg/50mL · Injection, Solution · Intravenous · Baxter Healthcare Company

NDC 00338-3814-24 · 24 BAG in 1 CARTON / 50 mL in 1 BAG · ANDA · View full market →

The short version

7 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “discontinuation of the manufacture of the drug”. One of its named manufacturing plants, Baxter Healthcare Corporation, failed FDA inspectionwithin the last two years — the agency’s most serious outcome.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$1.97per billing unit (300 MG)HCPCS J0736 · Jul 1, 2026
  • Part D plans paid (avg)$57.82per dosage unitgross, before rebates — matched by drug name · 2024

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$13.05
Reported to Texas DSHS · 2026 annual filing · Baxter Healthcare Corporation

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 300 MG
$1.974
HCPCS J0736 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$28,992
2,706 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $38.65 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
ANDA208084
TE code
AP
Approval date
Jun 28, 2017
Patents / exclusivity
None on file

Shortage history

  • Planned discontinuation — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18)Jun 1, 2026
  • Planned discontinuation — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06)Jun 1, 2026
  • In shortage now — Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)Mar 21, 2023
    Demand increase for the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)Mar 21, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)Mar 21, 2023
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months
  • In shortage now — Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)Mar 21, 2023
    Discontinuation of the manufacture of the drug
    month 42 — 2× the typical 20-month injectable shortage · model puts 31% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Clindamycin phosphate (Injection, Solution)

LabelerStrengthFirst seenLast seen
Baxter Healthcare CompanyCLINDAMYCIN PHOSPHATE 300 mg/50mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CompanyCLINDAMYCIN PHOSPHATE 900 mg/50mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CompanyCLINDAMYCIN PHOSPHATE 600 mg/50mLJul 15, 2026Sep 3, 2026
Medical Purchasing Solutions, LLCCLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Sep 3, 2026
Pharmacia & Upjohn Company LLCCLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Sep 3, 2026
Baxter Healthcare CorporationCLINDAMYCIN PHOSPHATE 600 mg/50mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationCLINDAMYCIN PHOSPHATE 900 mg/50mLJul 15, 2026Sep 2, 2026
ProPharma DistributionCLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsCLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Sep 2, 2026
Henry Schein, Inc.CLINDAMYCIN PHOSPHATE 150 mg/mLJul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Clindamycin phosphate — NDC 00338-3814-24," retrieved September 3, 2026, https://drugdashboards.com/drug/00338381424.

Free to cite with attribution — see how the data is put together.